AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02785965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Disposable, single-use, sterilized stainless-steel needles (Yunlong, Beijing, China; length 40/100 mm, diameter 0.30 mm) are inserted into waist, bilaterally. All of the six points are located in the Dai Meridian route corresponding to the ovaries. Four needles, 0.25mm in diameter and 25mm in length, are also placed in distal acupuncture points which are located in the feet and lower arms to enhance local points' effects. Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into GB26(Daimai) with a depth of 25-65mm by an angle of 15°, following the path of Dai Meridian (towards medial and downside). The other needles are inserted vertically into the acupoints with a depth of 10-30mm, depending on the thickness of muscles. Electro-acupuncture is applied to both sides of GB26 and ST25(Tianshu): cathode is connected to GB26; anode to ST25. Needles are stimulated electrically with low frequency (2 Hz) for 20 min.
Study NCT02785965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification
Description: The diet restricts patients to 1400 calories a day for 12 weeks.The exercise included 12 weeks of aerobic exercise in moderate level (60 to 70% of maximum heart rate), for 3 sessions a week, each session for 60 min. The exercises included: Warning up: 10 min, main phase (aerobic exercise): 40 min and cooling down: 10 min. Polar Pulse measuring device from China was used to control the intensity of the exercises.
Study NCT02785965 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle modification
Description: The diet restricts patients to 1400 calories a day for 12 weeks.The exercise included 12 weeks of aerobic exercise in moderate level (60 to 70% of maximum heart rate), for 3 sessions a week, each session for 60 min. The exercises included: Warning up: 10 min, main phase (aerobic exercise): 40 min and cooling down: 10 min. Polar Pulse measuring device from China was used to control the intensity of the exercises.
Study NCT01820936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1: PCI-32765
Description: Period 1 = Treatment D, Period 2 = Treatment C, Period 3 = Treatment A, Period 4 = Treatment B
Study NCT01820936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2: PCI-32765
Description: Period 1 = Treatment A, Period 2 = Treatment D, Period 3 = Treatment B, Period 4 = Treatment C
Study NCT01820936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 3: PCI-32765
Description: Period 1 = Treatment B, Period 2 = Treatment A, Period 3 = Treatment C, Period 4 = Treatment D
Study NCT01820936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4: PCI-32765
Description: Period 1 = Treatment C, Period 2 = Treatment B, Period 3 = Treatment D, Period 4 = Treatment A
Study NCT01820936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 5: PCI-32765
Description: After completion of the 4-way crossover, an additional separate cohort of 8 subjects were enrolled. These subjects participated in 1 treatment period to document safety and PK
Study NCT01274936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishe Pill
Description: Pill, 3.75 g, twice per day, four weeks
Study NCT01274936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qishe Placebo
Description: Pill, 3.75 g, twice per day, four weeks
Study NCT04559945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aveir VR Leadless Pacemaker System
Description: Patients will undergo an attempted leadless pacemaker implant
Study NCT03056560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TakeCARE (video bystander program)
Description: brief video encouraging active responses to high-risk situations for campus violence
Study NCT01106495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsation (EECP)
Description: EECP one hour per day, 5 hours a week for a total of 35- 36 hours over a 7 week period
Study NCT01106495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40 mg/d for 7 weeks as the guideline- driven standard medical treatment
Study NCT01106495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40 mg/d for 7 weeks as the guideline- driven standard medical treatment
Study NCT00473551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 intravenously over several hours on Day -13, followed by 1000 mg/m\^2 intravenously on Days -6, 1, and 8.
Study NCT00473551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine.
Study NCT00473551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 intravenously over 30 minutes once per day for 4 days, starting Day -6.
Study NCT00473551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 10 mg/kg continuous intravenous infusion for 4 hours for total of 6 doses (24 hours) following Cyclophosphamide.
Study NCT00473551 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Treatment
Description: 2Gy Total body radiation day before transplantation
Study NCT00473551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation (SCT)
Description: Allo CD34+ Selected SCT/Infusion of stem cells.
Study NCT00473551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 6 mg by mouth on day -2 followed by 2 mg daily from day -1 through day +7.
Study NCT00473551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anti-third Party Cytolytic T-lymphocytes (CTL)
Description: Intravenous infusion of anti-third party CTL.
Study NCT00510991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nippv
Study NCT01433757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin
Description: Ampicillin will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of Ampicillin will be given to the patient, to be taken in the same manner as described above.
Study NCT01433757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: The sugar pill will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of the sugar pill will be given to the patient, to be taken in the same manner as described above.
Study NCT00851682 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scan
Description: Each patient will undergo one, contrast-enhanced MRI scan prior to his planned, standard of care procedure, either radical prostatectomy or brachytherapy, depending on the study arm. Patients will be randomized to be imaged with either a phased array body coil or an endorectal coil.
Study NCT03570372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based treatment for adults with autism spectrum
Description: Internet-based CBT. The intervention includes 18 modules focusing on: Psychoeducation, individual goal setting, behavioral change, management strategies and stress management
Study NCT03570372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation about autism spectum disorder
Description: Self-studies by reading the book What does the disability mean ?: Living with autism / Asperger syndrome. Project Empowerment (2004), by Norrö \& Swing Åström, as well as a book of biographical stories of people who have ASD. The first book will be read during the first half of the project, and the second will be in the second half.
Study NCT00806676 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gardasil® Vaccine (FDA-approved vaccination regimen)
Description: Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.
Study NCT04454697 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tissue retractors
Description: Patients receive a tissue retractor to spare healthy tissue during the course of radiation
Study NCT04454697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tissue retractors
Description: Patients receive a tissue retractor to spare healthy tissue during the course of radiation
Study NCT03165435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV-MG01
Description: 3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
Study NCT03165435 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
Study NCT04608760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meksibel
Description: 2 ml solution
Study NCT02822950 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ceftazidime/avibactam
Description: Ceftazadime/avibactam dosing in ICU patients
Study NCT03406143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CGF injection
Description: CGF injection subdermally to expanded skin at the density of 0.02ml/cm2.
Study NCT03406143 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Saline will be injected into expanded skin
Study NCT00684450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titration protamine
Description: 10. Study group: celite ACT will be performed every 3 minutes during protamine infusion until ACT values suggest reach of a plateau (defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds.), time at which infusion will be stopped. 2cc of blood is required per ACT test, for a maximum total of 10cc.
Study NCT00684450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard administration of protamine
Description: 1.3 mg of Protamine for 100u héparine
Study NCT00105144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV
Study NCT00105144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: IV
Study NCT03161288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1005
Description: A human anti-OX40 ligand monoclonal antibody
Study NCT03161288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study NCT01958788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioural Treatment
Description: 12 weekly sessions of individual cognitive-behavioural treatment (CBT) targeting intolerance of uncertainty.
Study NCT03526354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole 4mg daily for 12 weeks
Study NCT03526354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Current antipsychotic medication for 12 weeks
Study NCT02378220 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenetic testing
Description: Pharmacogenetic testing via YouScript® Personalized Prescribing System
Study NCT03808389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor FMT
Description: Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from healthy donors and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the treatment group.
Study NCT03808389 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Autologous FMT
Description: Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from each patient and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the control group.
Study NCT06374472 — intervention group
Intervention type: PROCEDURE
Intervention: Osteosynthesis
Description: Some patients had osteosynthesis using a long construct, others had osteosynthesis using a short construct. Short constructs designated constructs only taking one level above and one level below the injury level (the fractured vertebra was not always included in the construct). The montages taking more than one level above or below the lesion were considered to be a long montage. Osteosynthesis is carried out using Cotrel Dubousset type rods and screws.
Study NCT03135171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
Study NCT03135171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Dose Levels two and three will receive 840 mg loading dose for cycle 1, followed by 420 mg in subsequent cycles, every 3 weeks.
Study NCT03135171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 4-8 mg/kg, administered intravenously every three weeks
Study NCT04098042 — intervention group
Intervention type: DEVICE
Intervention: Scaffold
Description: implantation of a Magmaris scaffold
Study NCT04349163 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: CD-RISC 25 questionnaire
Study NCT05590936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimenhydrinate Tablets
Description: 2 hours preoperative per os administration of 50 mg dimenhydrinate
Study NCT05590936 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ondansetron iv
Description: Intraoperative intravenous administration of 4 mg ondansetron
Study NCT03875209 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10E8.4/iMab
Description: bispecific monoclonal antibody
Study NCT02094963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 180mg loading and 90mg bid
Study NCT02094963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 600mg loading and 75mg qd
Study NCT03926754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.~Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days).
Study NCT03926754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mirabegron
Description: Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.~Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days).
Study NCT01764971 — intervention group
Intervention type: OTHER
Intervention: IQ assessment and visual- motor assessment
Description: Psychological examination and evaluation for both groups to diagnose those with behavioral and /or cognitive dysfunction.
Study NCT01764971 — intervention group
Intervention type: OTHER
Intervention: EEG,brain imaging
Description: For patients with cognitive or behavioral deficit, MRI brain and quantitative EEG will be done to identify any CNS abnormality.
Study NCT00800683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Description: BI 1356 dosed once daily
Study NCT00800683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching BI 1356 taken once daily
Study NCT00990054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: 240 mcg/kg/dose and proceeding to escalating dose levels for determination of the single-dose maximum tolerated dose (MTD) provided that there are no unacceptable dose limiting toxicities
Study NCT01848353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.
Study NCT01848353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.
Study NCT01624987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NET for Forensic Offender Rehabilitation (FORNET): a variant of Narrative Exposure Therapy
Description: During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the trained therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
Study NCT01624987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: The control group receives no intervention.
Study NCT03229408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Lean PCOS Arms: Salsalate 1.5 gm PO bid; Obese PCOS Arm: Salsalate 2.0 gm PO bid
Study NCT01764906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Iliac crest bone graft
Study NCT05471466 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical incision
Description: Surgical incisions to the neck as part of the management of the head and neck condition.
Study NCT02364570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose (100g)
Description: Ingestion of glucose (100g)
Study NCT02364570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose (75g)
Description: Ingestion of glucose (75g)
Study NCT02364570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Eggs
Description: Ingestion of 1.5 whole eggs
Study NCT02364570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg Whites
Description: Ingestion of 7 egg whites
Study NCT02364570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg Yolks
Description: Ingestion of 2 egg yolks
Study NCT03052075 — intervention group
Intervention type: OTHER
Intervention: Retrospective Data Review
Description: Retrospective, uncontrolled pre- and post-test design in a case series of approximately 250 patients who underwent parathyroidectomy at MD Anderson Cancer Center (years 1990 - 2013 ) and had bone density measures recorded at baseline and at one year post-surgery. Data extracted from the surgical oncology database for bone mineral density measures for each patient at multiple sites including the lumbar spine, total hip (right/left), femoral neck (right/left), and distal 1/3 radius. All measures recorded from two time points: presurgical (baseline) and postsurgical (all follow-up available dates beginning at 1 year post-parathyroidectomy).
Study NCT02395081 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 600 IU Vitamin D3 in prenatal vitamin
Description: Women will receive 600 IU 25(OH)D in prenatal vitamin.
Study NCT03229408 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Appears identical to experimental drug
Study NCT03779919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave
Description: Extracorporeal shock wave therapy uses acoustic waves to fragment calcific deposits. Variables of the settings include dose (low or high energy), duration (impulses), and the interval of administration.
Study NCT03779919 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: extracorporeal shock wave
Description: Extracorporeal shock wave therapy uses acoustic waves to fragment calcific deposits. Variables of the settings include dose (low or high energy), duration (impulses), and the interval of administration.
Study NCT04384393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART19 cells
Description: 0.2-60 x 10\^6 CAR T cells per kg body weight.
Study NCT03477513 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radation Therapy
Description: Personalized Radiation Therapy
Study NCT01587339 — intervention group
Intervention type: DRUG
Intervention: retigabine/ezogabine
Description: oral - all doses
Study NCT01587339 — intervention group
Intervention type: DRUG
Intervention: lacosamide
Description: oral - all doses
Study NCT01587339 — intervention group
Intervention type: DRUG
Intervention: zonisamide
Description: oral - all doses
Study NCT01587339 — intervention group
Intervention type: DRUG
Intervention: pregabalin
Description: oral - all doses
Study NCT01587339 — intervention group
Intervention type: DRUG
Intervention: eslicarbazepine
Description: oral - all doses
Study NCT04869254 — intervention group
Intervention type: OTHER
Intervention: Lower lymphocyte/ATG ratio
Study NCT04869254 — intervention group
Intervention type: OTHER
Intervention: Higher lymphocyte/ATG ratio